CDK4 and non-small cell lung carcinoma: Although early-stage clinical studies of CDK4/6 inhibitor (palbociclib, abemaciclib) monotherapy demonstrated good safety profiles in small populations of patients with advanced, previously treated NSCLC, the overall antitumor efficacy was limited and generally no better than that achieved with other second-line agents [14].